###begin article-title 0
Regulation of skeletal muscle sucrose, non-fermenting 1/AMP-activated protein kinase-related kinase (SNARK) by metabolic stress and diabetes
###end article-title 0
###begin title 1
Aims/hypothesis
###end title 1
###begin p 2
Sucrose, non-fermenting 1/AMP-activated protein kinase-related kinase (SNARK) is involved in cellular stress responses linked to obesity and type 2 diabetes. We determined the role of SNARK in response to metabolic stress and insulin action on glucose and lipid metabolism in skeletal muscle.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 86 88 86 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;</italic>
###xml 115 117 115 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;</italic>
###xml 123 126 <span type="species:ncbi:9606">men</span>
###xml 131 136 <span type="species:ncbi:9606">women</span>
Vastus lateralis skeletal muscle biopsies were obtained from normal glucose tolerant (n = 35) and type 2 diabetic (n = 31) men and women for SNARK expression studies. Primary myotube cultures were derived from biopsies obtained from normal glucose tolerant individuals for metabolic studies.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NUAK2</italic>
###xml 132 137 132 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 206 207 206 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 308 310 308 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 345 346 345 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 414 419 414 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 482 484 482 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 516 518 512 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 755 757 747 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 122 130 <span type="species:ncbi:9606">patients</span>
###xml 265 273 <span type="species:ncbi:9606">patients</span>
###xml 404 412 <span type="species:ncbi:9606">patients</span>
SNARK (also known as NUAK2) mRNA expression was unaltered between normal glucose tolerant individuals and type 2 diabetic patients. SNARK expression was increased in skeletal muscle from obese (BMI >31 kg/m2) normal glucose tolerant individuals and type 2 diabetic patients (1.4- and 1.4-fold, respectively, p < 0.05) vs overweight (BMI <28 kg/m2) normal glucose tolerant individuals and type 2 diabetic patients. SNARK mRNA was increased in myotubes exposed to palmitate (12-fold; p < 0.01), or TNF-alpha (25-fold, p < 0.05), but not to oleate, glucose or IL-6, whereas expression of the AMP-activated protein kinase alpha2 subunit was unaltered. Small interfering (si)RNA against SNARK reduced mRNA and protein in myotubes by 61% and 60%, respectively (p < 0.05). SNARK siRNA was without effect on basal or insulin-stimulated glucose uptake or lipid oxidation, and insufficient to rescue TNF-alpha- or palmitate-induced insulin resistance.
###end p 6
###begin title 7
Conclusions/interpretation
###end title 7
###begin p 8
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 49 54 <span type="species:ncbi:9606">human</span>
###xml 287 292 <span type="species:ncbi:9606">human</span>
Skeletal muscle SNARK expression is increased in human obesity, and in response to metabolic stressors, but not type 2 diabetes. Partial SNARK depletion failed to modify either glucose or lipid metabolism, or protect against TNF-alpha- or palmitate-induced insulin resistance in primary human myotubes.
###end p 8
###begin title 9
Keywords
###end title 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 291 292 291 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 294 295 294 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 665 666 665 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
The ability to adjust energy use and storage in times of fuel surplus or deficiency is vital for survival throughout evolution. AMP-activated protein kinase (AMPK) is known as a master regulator of glucose and lipid metabolism in mammals through sensing of the ratio of AMP:ATP in the cell [1, 2]. Upon activation of AMPK, anabolic energy-demanding pathways are switched off and catabolic ATP-producing pathways are activated, thereby controlling peripheral glucose and lipid homeostasis. Recently, a family of AMPK-related kinases has been described, thereby broadening the regulation of metabolism in response to cellular stress to include novel protein kinases [3].
###end p 11
###begin p 12
###xml 259 260 244 245 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 274 275 255 256 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 394 395 375 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 397 398 378 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 507 508 488 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 657 658 631 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 866 867 837 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 869 870 840 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 977 978 948 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 304 309 <span type="species:ncbi:9606">human</span>
AMPK is a heterotrimeric complex consisting of a catalytic AMP-sensitive alpha subunit and regulatory beta and gamma subunits. Twelve protein kinases (BRSK1, BRSK2, NUAK1, NUAK2, QIK, QSK, SIK, MARK1, MARK2, MARK3, MARK4 and MELK) closely related to AMPKalpha1 and AMPKalpha2 have been identified in the human kinome, thus forming a 14 kinase phylogenetic tree known as 'AMPK-related kinases' [3, 4]. LKB1, an upstream activating kinase of AMPK, phosphorylates and activates 11 of the AMPK-related kinases [3]. Although the role of AMPK-related kinases is largely unknown, they do not appear to interact with the regulatory beta and gamma subunits of AMPK [5]. Furthermore, the majority of the AMPK-related kinases are not activated by AMP or pharmacological activators of AMPK including 5-aminoimidazole-4-carboxamide-1beta-4-ribofuranoside (AICAR) and phenformin [3, 6]. Recent evidence suggests that skeletal muscle-selective knockout of LKB1 increases insulin sensitivity [7], possibly implicating these novel AMPK-related protein kinases in the regulation of glucose homeostasis.
###end p 12
###begin p 13
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Snark</italic>
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nuak2</italic>
###xml 201 202 201 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 205 210 205 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 283 284 283 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 287 292 287 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 394 396 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 408 413 408 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Snark</italic>
###xml 483 485 483 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 754 756 754 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 758 760 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 843 845 843 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 1024 1026 1024 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 1028 1030 1028 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 1032 1034 1032 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 55 59 <span type="species:ncbi:10090">mice</span>
###xml 307 312 <span type="species:ncbi:9606">human</span>
###xml 402 406 <span type="species:ncbi:10116">rats</span>
###xml 1096 1102 <span type="species:ncbi:9606">humans</span>
Haploinsufficient Snark (also known as Nuak2) knockout mice develop obesity, hepatic steatosis, altered serum lipid profiles, hyperinsulinaemia, hyperglycaemia and impaired glucose tolerance with age [8]. SNARK was first identified as an ultraviolet B-induced gene in keratinocytes [9]. SNARK is located on human chromosome 1q32 and is translated into a single protein of approximately 76 kDa [10]. In rats, Snark is expressed in multiple tissues, with highest expression in kidney [11]. Sucrose, non-fermenting 1/AMP-activated protein kinase-related kinase (SNARK) is activated in a cell-type-specific manner by a variety of stressors including hyperosmotic stress, DNA damage and oxidative stress, as well as nutrients including glucose and glutamine [10, 11]. Several aspects of SNARK activation and regulation are broadly similar to AMPK [12]. For example, SNARK and AMPK are both AMP-responsive and activated by treatments known to increase the AMP:ATP ratio, including glucose deprivation and chemical ATP production [10, 11, 13]. Nevertheless, the metabolic role of SNARK, particularly in humans and at the cellular level in skeletal muscle, is incompletely resolved.
###end p 13
###begin p 14
###xml 11 16 11 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Snark</italic>
###xml 77 78 77 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 35 39 <span type="species:ncbi:10090">mice</span>
###xml 528 533 <span type="species:ncbi:9606">human</span>
Given that Snark-haploinsufficient mice become obese and glucose-intolerant [8], this AMPK-related protein kinase may play a permissive role in energy metabolism. Thus, we tested the hypothesis that SNARK is involved in cellular stress responses associated with obesity and type 2 diabetes. Since skeletal muscle plays an important role in the regulation of whole-body glucose uptake, the aim of this study was to determine the role of SNARK in response to metabolic stress and insulin action on glucose and lipid metabolism in human skeletal muscle.
###end p 14
###begin title 15
Methods
###end title 15
###begin p 16
###xml 0 46 0 46 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Study participants and muscle biopsy procedure</bold>
###xml 465 466 465 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 715 722 715 722 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 722 749 722 749 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="17">Participant characteristics</p>
###xml 722 749 722 749 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="17">Participant characteristics</p></caption>
###xml 749 749 749 749 <th xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 749 752 749 752 <th xmlns:xlink="http://www.w3.org/1999/xlink">Sex</th>
###xml 752 763 752 763 <th xmlns:xlink="http://www.w3.org/1999/xlink">Age (years)</th>
###xml 772 773 772 773 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 763 774 763 774 <th xmlns:xlink="http://www.w3.org/1999/xlink">BMI (kg/m<sup>2</sup>)</th>
###xml 774 798 774 798 <th xmlns:xlink="http://www.w3.org/1999/xlink">Fasting glucose (mmol/l)</th>
###xml 801 803 801 803 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1c</sub>
###xml 798 807 798 807 <th xmlns:xlink="http://www.w3.org/1999/xlink">HbA<sub>1c</sub> (%)</th>
###xml 807 831 807 831 <th xmlns:xlink="http://www.w3.org/1999/xlink">Triacylglycerol (mmol/l)</th>
###xml 831 847 831 847 <th xmlns:xlink="http://www.w3.org/1999/xlink">Insulin (pmol/l)</th>
###xml 847 855 847 855 <th xmlns:xlink="http://www.w3.org/1999/xlink">HOMA2-IR</th>
###xml 749 855 749 855 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th/><th>Sex</th><th>Age (years)</th><th>BMI (kg/m<sup>2</sup>)</th><th>Fasting glucose (mmol/l)</th><th>HbA<sub>1c</sub> (%)</th><th>Triacylglycerol (mmol/l)</th><th>Insulin (pmol/l)</th><th>HOMA2-IR</th></tr>
###xml 749 855 749 855 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th/><th>Sex</th><th>Age (years)</th><th>BMI (kg/m<sup>2</sup>)</th><th>Fasting glucose (mmol/l)</th><th>HbA<sub>1c</sub> (%)</th><th>Triacylglycerol (mmol/l)</th><th>Insulin (pmol/l)</th><th>HOMA2-IR</th></tr></thead>
###xml 855 878 855 878 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="9">Normal glucose tolerant</td>
###xml 855 878 855 878 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="9">Normal glucose tolerant</td></tr>
###xml 891 892 891 892 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 878 892 878 892 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;BMI &lt;28&#160;kg/m<sup>2</sup></td>
###xml 892 900 892 900 <td xmlns:xlink="http://www.w3.org/1999/xlink">10 F/8&#160;M</td>
###xml 900 908 900 906 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">59&#8201;&#177;&#8201;1</td>
###xml 908 920 906 916 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">26.2&#8201;&#177;&#8201;0.2</td>
###xml 920 931 916 925 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">5.3&#8201;&#177;&#8201;0.1</td>
###xml 931 943 925 935 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">4.6&#8201;&#177;&#8201;0.05</td>
###xml 943 956 935 946 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">1.15&#8201;&#177;&#8201;0.14</td>
###xml 956 968 946 956 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">51.2&#8201;&#177;&#8201;9.2</td>
###xml 968 979 956 965 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">1.0&#8201;&#177;&#8201;0.2</td>
###xml 878 979 878 965 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;BMI &lt;28&#160;kg/m<sup>2</sup></td><td>10 F/8&#160;M</td><td char="&#177;" align="char">59&#8201;&#177;&#8201;1</td><td char="&#177;" align="char">26.2&#8201;&#177;&#8201;0.2</td><td char="&#177;" align="char">5.3&#8201;&#177;&#8201;0.1</td><td char="&#177;" align="char">4.6&#8201;&#177;&#8201;0.05</td><td char="&#177;" align="char">1.15&#8201;&#177;&#8201;0.14</td><td char="&#177;" align="char">51.2&#8201;&#177;&#8201;9.2</td><td char="&#177;" align="char">1.0&#8201;&#177;&#8201;0.2</td></tr>
###xml 992 993 978 979 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 979 993 965 979 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;BMI &gt;31&#160;kg/m<sup>2</sup></td>
###xml 993 1001 979 987 <td xmlns:xlink="http://www.w3.org/1999/xlink">11 F/6&#160;M</td>
###xml 1001 1009 987 993 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">61&#8201;&#177;&#8201;1</td>
###xml 1009 1022 993 1004 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">34.4&#8201;&#177;&#8201;0.9*</td>
###xml 1022 1033 1004 1013 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">5.5&#8201;&#177;&#8201;0.1</td>
###xml 1033 1046 1013 1024 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">4.8&#8201;&#177;&#8201;0.07*</td>
###xml 1046 1059 1024 1035 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">1.49&#8201;&#177;&#8201;0.14</td>
###xml 1059 1071 1035 1045 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">59.7&#8201;&#177;&#8201;7.1</td>
###xml 1071 1082 1045 1054 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">1.1&#8201;&#177;&#8201;0.1</td>
###xml 979 1082 965 1054 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;BMI &gt;31&#160;kg/m<sup>2</sup></td><td>11 F/6&#160;M</td><td char="&#177;" align="char">61&#8201;&#177;&#8201;1</td><td char="&#177;" align="char">34.4&#8201;&#177;&#8201;0.9*</td><td char="&#177;" align="char">5.5&#8201;&#177;&#8201;0.1</td><td char="&#177;" align="char">4.8&#8201;&#177;&#8201;0.07*</td><td char="&#177;" align="char">1.49&#8201;&#177;&#8201;0.14</td><td char="&#177;" align="char">59.7&#8201;&#177;&#8201;7.1</td><td char="&#177;" align="char">1.1&#8201;&#177;&#8201;0.1</td></tr>
###xml 1082 1097 1054 1069 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="9">Type 2 diabetic</td>
###xml 1082 1097 1054 1069 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="9">Type 2 diabetic</td></tr>
###xml 1110 1111 1082 1083 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1097 1111 1069 1083 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;BMI &lt;28&#160;kg/m<sup>2</sup></td>
###xml 1111 1119 1083 1091 <td xmlns:xlink="http://www.w3.org/1999/xlink">2 F/12&#160;M</td>
###xml 1119 1127 1091 1097 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">60&#8201;&#177;&#8201;1</td>
###xml 1127 1140 1097 1108 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">27.0&#8201;&#177;&#8201;0.3*</td>
###xml 1140 1152 1108 1118 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">7.8&#8201;&#177;&#8201;0.4*</td>
###xml 1152 1165 1118 1129 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">6.1&#8201;&#177;&#8201;0.23*</td>
###xml 1165 1178 1129 1140 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">1.34&#8201;&#177;&#8201;0.13</td>
###xml 1178 1190 1140 1150 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">53.0&#8201;&#177;&#8201;6.5</td>
###xml 1190 1201 1150 1159 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">1.1&#8201;&#177;&#8201;0.1</td>
###xml 1097 1201 1069 1159 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;BMI &lt;28&#160;kg/m<sup>2</sup></td><td>2 F/12&#160;M</td><td char="&#177;" align="char">60&#8201;&#177;&#8201;1</td><td char="&#177;" align="char">27.0&#8201;&#177;&#8201;0.3*</td><td char="&#177;" align="char">7.8&#8201;&#177;&#8201;0.4*</td><td char="&#177;" align="char">6.1&#8201;&#177;&#8201;0.23*</td><td char="&#177;" align="char">1.34&#8201;&#177;&#8201;0.13</td><td char="&#177;" align="char">53.0&#8201;&#177;&#8201;6.5</td><td char="&#177;" align="char">1.1&#8201;&#177;&#8201;0.1</td></tr>
###xml 1214 1215 1172 1173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1201 1215 1159 1173 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;BMI &gt;31&#160;kg/m<sup>2</sup></td>
###xml 1215 1223 1173 1181 <td xmlns:xlink="http://www.w3.org/1999/xlink">3 F/14&#160;M</td>
###xml 1223 1231 1181 1187 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">60&#8201;&#177;&#8201;1</td>
###xml 1231 1244 1187 1198 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">34.5&#8201;&#177;&#8201;0.8*</td>
###xml 1244 1256 1198 1208 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">7.8&#8201;&#177;&#8201;0.4*</td>
###xml 1256 1269 1208 1219 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">5.9&#8201;&#177;&#8201;0.19*</td>
###xml 1269 1283 1219 1231 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">1.53&#8201;&#177;&#8201;0.10*</td>
###xml 1283 1297 1231 1243 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">91.4&#8201;&#177;&#8201;11.5*</td>
###xml 1297 1310 1243 1254 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">1.9&#8201;&#177;&#8201;0.21*</td>
###xml 1201 1310 1159 1254 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;BMI &gt;31&#160;kg/m<sup>2</sup></td><td>3 F/14&#160;M</td><td char="&#177;" align="char">60&#8201;&#177;&#8201;1</td><td char="&#177;" align="char">34.5&#8201;&#177;&#8201;0.8*</td><td char="&#177;" align="char">7.8&#8201;&#177;&#8201;0.4*</td><td char="&#177;" align="char">5.9&#8201;&#177;&#8201;0.19*</td><td char="&#177;" align="char">1.53&#8201;&#177;&#8201;0.10*</td><td char="&#177;" align="char">91.4&#8201;&#177;&#8201;11.5*</td><td char="&#177;" align="char">1.9&#8201;&#177;&#8201;0.21*</td></tr>
###xml 855 1310 855 1254 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="9">Normal glucose tolerant</td></tr><tr><td>&#160;BMI &lt;28&#160;kg/m<sup>2</sup></td><td>10 F/8&#160;M</td><td char="&#177;" align="char">59&#8201;&#177;&#8201;1</td><td char="&#177;" align="char">26.2&#8201;&#177;&#8201;0.2</td><td char="&#177;" align="char">5.3&#8201;&#177;&#8201;0.1</td><td char="&#177;" align="char">4.6&#8201;&#177;&#8201;0.05</td><td char="&#177;" align="char">1.15&#8201;&#177;&#8201;0.14</td><td char="&#177;" align="char">51.2&#8201;&#177;&#8201;9.2</td><td char="&#177;" align="char">1.0&#8201;&#177;&#8201;0.2</td></tr><tr><td>&#160;BMI &gt;31&#160;kg/m<sup>2</sup></td><td>11 F/6&#160;M</td><td char="&#177;" align="char">61&#8201;&#177;&#8201;1</td><td char="&#177;" align="char">34.4&#8201;&#177;&#8201;0.9*</td><td char="&#177;" align="char">5.5&#8201;&#177;&#8201;0.1</td><td char="&#177;" align="char">4.8&#8201;&#177;&#8201;0.07*</td><td char="&#177;" align="char">1.49&#8201;&#177;&#8201;0.14</td><td char="&#177;" align="char">59.7&#8201;&#177;&#8201;7.1</td><td char="&#177;" align="char">1.1&#8201;&#177;&#8201;0.1</td></tr><tr><td colspan="9">Type 2 diabetic</td></tr><tr><td>&#160;BMI &lt;28&#160;kg/m<sup>2</sup></td><td>2 F/12&#160;M</td><td char="&#177;" align="char">60&#8201;&#177;&#8201;1</td><td char="&#177;" align="char">27.0&#8201;&#177;&#8201;0.3*</td><td char="&#177;" align="char">7.8&#8201;&#177;&#8201;0.4*</td><td char="&#177;" align="char">6.1&#8201;&#177;&#8201;0.23*</td><td char="&#177;" align="char">1.34&#8201;&#177;&#8201;0.13</td><td char="&#177;" align="char">53.0&#8201;&#177;&#8201;6.5</td><td char="&#177;" align="char">1.1&#8201;&#177;&#8201;0.1</td></tr><tr><td>&#160;BMI &gt;31&#160;kg/m<sup>2</sup></td><td>3 F/14&#160;M</td><td char="&#177;" align="char">60&#8201;&#177;&#8201;1</td><td char="&#177;" align="char">34.5&#8201;&#177;&#8201;0.8*</td><td char="&#177;" align="char">7.8&#8201;&#177;&#8201;0.4*</td><td char="&#177;" align="char">5.9&#8201;&#177;&#8201;0.19*</td><td char="&#177;" align="char">1.53&#8201;&#177;&#8201;0.10*</td><td char="&#177;" align="char">91.4&#8201;&#177;&#8201;11.5*</td><td char="&#177;" align="char">1.9&#8201;&#177;&#8201;0.21*</td></tr></tbody>
###xml 749 1310 749 1254 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th/><th>Sex</th><th>Age (years)</th><th>BMI (kg/m<sup>2</sup>)</th><th>Fasting glucose (mmol/l)</th><th>HbA<sub>1c</sub> (%)</th><th>Triacylglycerol (mmol/l)</th><th>Insulin (pmol/l)</th><th>HOMA2-IR</th></tr></thead><tbody><tr><td colspan="9">Normal glucose tolerant</td></tr><tr><td>&#160;BMI &lt;28&#160;kg/m<sup>2</sup></td><td>10 F/8&#160;M</td><td char="&#177;" align="char">59&#8201;&#177;&#8201;1</td><td char="&#177;" align="char">26.2&#8201;&#177;&#8201;0.2</td><td char="&#177;" align="char">5.3&#8201;&#177;&#8201;0.1</td><td char="&#177;" align="char">4.6&#8201;&#177;&#8201;0.05</td><td char="&#177;" align="char">1.15&#8201;&#177;&#8201;0.14</td><td char="&#177;" align="char">51.2&#8201;&#177;&#8201;9.2</td><td char="&#177;" align="char">1.0&#8201;&#177;&#8201;0.2</td></tr><tr><td>&#160;BMI &gt;31&#160;kg/m<sup>2</sup></td><td>11 F/6&#160;M</td><td char="&#177;" align="char">61&#8201;&#177;&#8201;1</td><td char="&#177;" align="char">34.4&#8201;&#177;&#8201;0.9*</td><td char="&#177;" align="char">5.5&#8201;&#177;&#8201;0.1</td><td char="&#177;" align="char">4.8&#8201;&#177;&#8201;0.07*</td><td char="&#177;" align="char">1.49&#8201;&#177;&#8201;0.14</td><td char="&#177;" align="char">59.7&#8201;&#177;&#8201;7.1</td><td char="&#177;" align="char">1.1&#8201;&#177;&#8201;0.1</td></tr><tr><td colspan="9">Type 2 diabetic</td></tr><tr><td>&#160;BMI &lt;28&#160;kg/m<sup>2</sup></td><td>2 F/12&#160;M</td><td char="&#177;" align="char">60&#8201;&#177;&#8201;1</td><td char="&#177;" align="char">27.0&#8201;&#177;&#8201;0.3*</td><td char="&#177;" align="char">7.8&#8201;&#177;&#8201;0.4*</td><td char="&#177;" align="char">6.1&#8201;&#177;&#8201;0.23*</td><td char="&#177;" align="char">1.34&#8201;&#177;&#8201;0.13</td><td char="&#177;" align="char">53.0&#8201;&#177;&#8201;6.5</td><td char="&#177;" align="char">1.1&#8201;&#177;&#8201;0.1</td></tr><tr><td>&#160;BMI &gt;31&#160;kg/m<sup>2</sup></td><td>3 F/14&#160;M</td><td char="&#177;" align="char">60&#8201;&#177;&#8201;1</td><td char="&#177;" align="char">34.5&#8201;&#177;&#8201;0.8*</td><td char="&#177;" align="char">7.8&#8201;&#177;&#8201;0.4*</td><td char="&#177;" align="char">5.9&#8201;&#177;&#8201;0.19*</td><td char="&#177;" align="char">1.53&#8201;&#177;&#8201;0.10*</td><td char="&#177;" align="char">91.4&#8201;&#177;&#8201;11.5*</td><td char="&#177;" align="char">1.9&#8201;&#177;&#8201;0.21*</td></tr></tbody></table>
###xml 1310 1331 1254 1273 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="18">Data are means&#8201;&#177;&#8201;SE</p>
###xml 1332 1334 1274 1276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 1408 1409 1350 1351 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1331 1409 1273 1351 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="19">*<italic>p&#8201;</italic>&lt;&#8201;0.05 compared with normal glucose tolerant individuals with BMI &lt;28&#160;kg/m<sup>2</sup></p>
###xml 1409 1427 1351 1369 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="20">F, female; M, male</p>
###xml 1310 1427 1254 1369 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="18">Data are means&#8201;&#177;&#8201;SE</p><p textid="19">*<italic>p&#8201;</italic>&lt;&#8201;0.05 compared with normal glucose tolerant individuals with BMI &lt;28&#160;kg/m<sup>2</sup></p><p textid="20">F, female; M, male</p></table-wrap-foot>
###xml 715 1427 715 1369 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="17">Participant characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Sex</th><th>Age (years)</th><th>BMI (kg/m<sup>2</sup>)</th><th>Fasting glucose (mmol/l)</th><th>HbA<sub>1c</sub> (%)</th><th>Triacylglycerol (mmol/l)</th><th>Insulin (pmol/l)</th><th>HOMA2-IR</th></tr></thead><tbody><tr><td colspan="9">Normal glucose tolerant</td></tr><tr><td>&#160;BMI &lt;28&#160;kg/m<sup>2</sup></td><td>10 F/8&#160;M</td><td char="&#177;" align="char">59&#8201;&#177;&#8201;1</td><td char="&#177;" align="char">26.2&#8201;&#177;&#8201;0.2</td><td char="&#177;" align="char">5.3&#8201;&#177;&#8201;0.1</td><td char="&#177;" align="char">4.6&#8201;&#177;&#8201;0.05</td><td char="&#177;" align="char">1.15&#8201;&#177;&#8201;0.14</td><td char="&#177;" align="char">51.2&#8201;&#177;&#8201;9.2</td><td char="&#177;" align="char">1.0&#8201;&#177;&#8201;0.2</td></tr><tr><td>&#160;BMI &gt;31&#160;kg/m<sup>2</sup></td><td>11 F/6&#160;M</td><td char="&#177;" align="char">61&#8201;&#177;&#8201;1</td><td char="&#177;" align="char">34.4&#8201;&#177;&#8201;0.9*</td><td char="&#177;" align="char">5.5&#8201;&#177;&#8201;0.1</td><td char="&#177;" align="char">4.8&#8201;&#177;&#8201;0.07*</td><td char="&#177;" align="char">1.49&#8201;&#177;&#8201;0.14</td><td char="&#177;" align="char">59.7&#8201;&#177;&#8201;7.1</td><td char="&#177;" align="char">1.1&#8201;&#177;&#8201;0.1</td></tr><tr><td colspan="9">Type 2 diabetic</td></tr><tr><td>&#160;BMI &lt;28&#160;kg/m<sup>2</sup></td><td>2 F/12&#160;M</td><td char="&#177;" align="char">60&#8201;&#177;&#8201;1</td><td char="&#177;" align="char">27.0&#8201;&#177;&#8201;0.3*</td><td char="&#177;" align="char">7.8&#8201;&#177;&#8201;0.4*</td><td char="&#177;" align="char">6.1&#8201;&#177;&#8201;0.23*</td><td char="&#177;" align="char">1.34&#8201;&#177;&#8201;0.13</td><td char="&#177;" align="char">53.0&#8201;&#177;&#8201;6.5</td><td char="&#177;" align="char">1.1&#8201;&#177;&#8201;0.1</td></tr><tr><td>&#160;BMI &gt;31&#160;kg/m<sup>2</sup></td><td>3 F/14&#160;M</td><td char="&#177;" align="char">60&#8201;&#177;&#8201;1</td><td char="&#177;" align="char">34.5&#8201;&#177;&#8201;0.8*</td><td char="&#177;" align="char">7.8&#8201;&#177;&#8201;0.4*</td><td char="&#177;" align="char">5.9&#8201;&#177;&#8201;0.19*</td><td char="&#177;" align="char">1.53&#8201;&#177;&#8201;0.10*</td><td char="&#177;" align="char">91.4&#8201;&#177;&#8201;11.5*</td><td char="&#177;" align="char">1.9&#8201;&#177;&#8201;0.21*</td></tr></tbody></table><table-wrap-foot><p textid="18">Data are means&#8201;&#177;&#8201;SE</p><p textid="19">*<italic>p&#8201;</italic>&lt;&#8201;0.05 compared with normal glucose tolerant individuals with BMI &lt;28&#160;kg/m<sup>2</sup></p><p textid="20">F, female; M, male</p></table-wrap-foot></table-wrap>
###xml 6 18 <span type="species:ncbi:9606">participants</span>
###xml 249 252 <span type="species:ncbi:9606">men</span>
###xml 257 262 <span type="species:ncbi:9606">women</span>
###xml 429 441 <span type="species:ncbi:9606">participants</span>
###xml 701 713 <span type="species:ncbi:9606">participants</span>
Study participants and muscle biopsy procedure Biopsies were obtained using a Weil-Blakesley conchotome from vastus lateralis skeletal muscle under local anaesthesia (lidocaine hydrochloride 5 mg/ml) from normal glucose tolerant and type 2 diabetic men and women for mRNA expression analysis of the gene encoding SNARK. Biopsies were snap-frozen and stored in liquid nitrogen until use. The clinical characteristics of the study participants are presented in Table 1. HOMA2-insulin resistance (IR) values were determined using the HOMA calculator (). The regional ethical committee at Karolinska Institutet approved all study protocols. Informed written and verbal consent was received from all study participants. Table 1Participant characteristicsSexAge (years)BMI (kg/m2)Fasting glucose (mmol/l)HbA1c (%)Triacylglycerol (mmol/l)Insulin (pmol/l)HOMA2-IRNormal glucose tolerant BMI <28 kg/m210 F/8 M59 +/- 126.2 +/- 0.25.3 +/- 0.14.6 +/- 0.051.15 +/- 0.1451.2 +/- 9.21.0 +/- 0.2 BMI >31 kg/m211 F/6 M61 +/- 134.4 +/- 0.9*5.5 +/- 0.14.8 +/- 0.07*1.49 +/- 0.1459.7 +/- 7.11.1 +/- 0.1Type 2 diabetic BMI <28 kg/m22 F/12 M60 +/- 127.0 +/- 0.3*7.8 +/- 0.4*6.1 +/- 0.23*1.34 +/- 0.1353.0 +/- 6.51.1 +/- 0.1 BMI >31 kg/m23 F/14 M60 +/- 134.5 +/- 0.8*7.8 +/- 0.4*5.9 +/- 0.19*1.53 +/- 0.10*91.4 +/- 11.5*1.9 +/- 0.21*Data are means +/- SE*p < 0.05 compared with normal glucose tolerant individuals with BMI <28 kg/m2F, female; M, male
###end p 16
###begin p 17
###xml 0 11 <span type="species:ncbi:9606">Participant</span>
Participant characteristics
###end p 17
###begin p 18
Data are means +/- SE
###end p 18
###begin p 19
###xml 1 3 1 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 77 78 77 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
*p < 0.05 compared with normal glucose tolerant individuals with BMI <28 kg/m2
###end p 19
###begin p 20
F, female; M, male
###end p 20
###begin p 21
###xml 0 53 0 53 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Skeletal muscle cell cultures and in vitro treatments</bold>
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 499 504 499 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 674 679 670 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 762 767 758 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 934 939 930 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 1192 1194 1188 1190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
Skeletal muscle cell cultures and in vitro treatments Skeletal muscle cell cultures were established from satellite cells isolated from vastus lateralis skeletal muscle biopsies obtained from normal glucose tolerant individuals. Satellite cells were isolated by trypsin-EDTA digestion, and myoblasts were cultured and differentiated into myotubes as previously described [14]. Myotubes were used to test the effects of a variety of cellular stressors, including nutrients, hormones or cytokines, on SNARK mRNA expression. Myotubes were treated with palmitate (0.25 mmol/l), oleate (0.25 mmol/l), glucose (25 mmol/l), TNF-alpha (20 ng/ml) or IL-6 (20 ng/ml) for 2 or 7 days. SNARK mRNA expression was determined as described below.To determine the direct role of SNARK on basal and insulin-stimulated glucose and lipid metabolism, myoblasts were transfected with small interfering (si) RNA against a scrambled non-specific sequence or SNARK (80 pmol) (Ambion/Applied Biosystems, Foster City, USA) for 16 h before initiation of differentiation and also after 2 days into the differentiation programme using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) in serum- and antibiotic-free DMEM [15]. Glucose incorporation into glycogen and lipid oxidation were determined, as described below.
###end p 21
###begin p 22
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink">SNARK mRNA expression</bold>
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 637 642 637 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 647 657 647 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AMPK&#945;2</italic>
###xml 673 679 669 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRKAA2</italic>
SNARK mRNA expressionSNARK mRNA expression was assessed in vastus lateralis skeletal muscle biopsies or primary skeletal muscle cell cultures (myotubes) using quantitative RT-PCR (ABI PRISM 7000 Sequence Detector System; Applied Biosystems). Total RNA was purified from skeletal muscle biopsies using Trizol reagent (Invitrogen, Carlsbad, CA, USA) and from myotubes using an RNeasy Mini Kit (Invitrogen). Purified RNA was treated with DNase I using a DNA-free kit (Ambion) and cDNA synthesis was performed with a SuperScript First Strand Synthesis System (Invitrogen). TaqMan gene expression assays (Hs00388292_m1 and Hs00178903_m1) for SNARK and AMPKalpha2 (also known as PRKAA2) mRNA expression were independently used in multiplex, with beta2-microglobulin as a reference gene (Applied Biosystems). All samples where assayed in duplicate. The mRNA relative abundance was calculated using the standard curve method as described by Applied Biosystems.
###end p 22
###begin p 23
###xml 0 43 0 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Glycogen synthesis in skeletal muscle cells</bold>
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 250 251 250 251 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 255 257 255 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink">14</sup>
###xml 564 566 560 562 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 568 570 564 566 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
Glycogen synthesis in skeletal muscle cells Glucose incorporation into glycogen was determined as described [16]. Myotubes were incubated in the absence or presence of either 6 or 60 nmol/l insulin for 30 min and thereafter incubated for 90 min with d-[U-14C]glucose (3700 Bq/ml; Amersham, Uppsala, Sweden) in DMEM (1 g glucose/l). When indicated, myotubes were exposed to either palmitate (0.25 mmol/l) or TNF-alpha (20 ng/ml) for 48 h before the experiment was performed. Experiments were performed in duplicate. Results are reported as nmol glucose (mg protein)-1 h-1.
###end p 23
###begin p 24
###xml 0 40 0 40 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Lipid oxidation in skeletal muscle cells</bold>
###xml 94 95 94 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 143 144 143 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 384 385 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 387 388 387 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 807 808 807 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 857 858 857 858 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 1144 1146 1144 1146 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 1148 1150 1148 1150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
Lipid oxidation in skeletal muscle cells NEFA oxidation was assessed by exposing myotubes to [3H]palmitic acid and measuring the production of 3H-labelled water. Myotubes were cultured in six well plates and serum starved overnight. Cells were washed once with PBS and incubated for 5.5 h with 1 ml DMEM (1 g glucose/l), supplemented with fatty acid-free BSA (0.2% wt/vol.) and [9,10(n)-3H]palmitic acid (1850 Bq/ml; Amersham), with or without insulin (120 nmol/l) or AICAR (1 mmol/l; Toronto Research Chemicals, Toronto, ON, Canada). To absorb non-metabolised palmitate, 0.2 ml of the cell supernatant was mixed with 0.8 ml charcoal slurry (0.1 g charcoal powder in 1 ml 0.02 mol/l TRIS-HCl buffer, pH 7.5) in a 2 ml Eppendorf tube and shaken for 30 min. Samples were subjected to centrifugation at 18,500xg for 15 min, after which 0.3 ml supernatant with 3H-labelled-bound water was withdrawn, and radioactivity was determined by liquid scintillation counting (WinSpectral 1414 Liquid Scintillation Counter; Wallac, Turku, Finland). Each experiment was performed in duplicate. Results are reported as per cent converted palmitate (mg protein)-1 h-1.
###end p 24
###begin p 25
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Western blot analysis</bold>
Western blot analysis Lysates were prepared from myotubes transfected with siRNA against a scrambled sequence or SNARK. Proteins were separated by SDS-PAGE and subjected to immunoblot analysis with an antibody directed against SNARK (Proteintech, Manchester, UK). Proteins where visualised by enhanced chemiluminescence and quantified by densiometry. Results are reported as arbitrary units and normalised to a loading control (desmin).
###end p 25
###begin p 26
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Statistics</bold>
###xml 106 107 104 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Statistics Results are presented as means +/- SE. Differences between groups were determined by Student's t test or two-way ANOVA. When ANOVA was applied, pair-wise multiple comparison procedures were performed using the Holm-Sidak method at a significance level of 0.05.
###end p 26
###begin title 27
Results
###end title 27
###begin p 28
###xml 0 83 0 83 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Skeletal muscle SNARK mRNA expression is increased with obesity but not in diabetes</bold>
###xml 83 88 83 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 234 235 234 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 307 309 307 309 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1c</sub>
###xml 369 371 369 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 508 509 508 509 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 538 539 538 539 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 607 609 607 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 618 623 618 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 721 722 721 722 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 787 788 787 788 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 791 796 791 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 877 878 877 878 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 932 933 932 933 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 936 941 936 941 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 1050 1056 1050 1056 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 1056 1061 1056 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 1225 1226 1225 1226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1256 1257 1256 1257 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1338 1340 1336 1338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;</italic>
###xml 1362 1364 1360 1362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 1438 1439 1436 1437 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1056 1439 1056 1437 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="29"><italic>SNARK</italic> mRNA expression was determined in vastus lateralis skeletal muscle biopsies from normal glucose tolerant individuals and type 2 diabetic patients with BMI &lt;28&#160;kg/m<sup>2</sup> (white bars) and BMI &gt;31&#160;kg/m<sup>2</sup> (black bars). Result are reported in arbitrary units (A.U.) as means&#8201;&#177;&#8201;SE for <italic>n&#8201;</italic>=&#8201;14&#8211;18 individuals. *<italic>p&#8201;</italic>&lt;&#8201;0.05 compared with normal glucose tolerant individuals with BMI &lt;28&#160;kg/m<sup>2</sup></p>
###xml 1056 1439 1056 1437 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="29"><italic>SNARK</italic> mRNA expression was determined in vastus lateralis skeletal muscle biopsies from normal glucose tolerant individuals and type 2 diabetic patients with BMI &lt;28&#160;kg/m<sup>2</sup> (white bars) and BMI &gt;31&#160;kg/m<sup>2</sup> (black bars). Result are reported in arbitrary units (A.U.) as means&#8201;&#177;&#8201;SE for <italic>n&#8201;</italic>=&#8201;14&#8211;18 individuals. *<italic>p&#8201;</italic>&lt;&#8201;0.05 compared with normal glucose tolerant individuals with BMI &lt;28&#160;kg/m<sup>2</sup></p></caption>
###xml 1439 1439 1437 1437 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="125_2009_1465_Fig1_HTML" id="MO1"/>
###xml 1050 1439 1050 1437 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="29"><italic>SNARK</italic> mRNA expression was determined in vastus lateralis skeletal muscle biopsies from normal glucose tolerant individuals and type 2 diabetic patients with BMI &lt;28&#160;kg/m<sup>2</sup> (white bars) and BMI &gt;31&#160;kg/m<sup>2</sup> (black bars). Result are reported in arbitrary units (A.U.) as means&#8201;&#177;&#8201;SE for <italic>n&#8201;</italic>=&#8201;14&#8211;18 individuals. *<italic>p&#8201;</italic>&lt;&#8201;0.05 compared with normal glucose tolerant individuals with BMI &lt;28&#160;kg/m<sup>2</sup></p></caption><graphic position="anchor" xlink:href="125_2009_1465_Fig1_HTML" id="MO1"/></fig>
###xml 214 217 <span type="species:ncbi:9606">men</span>
###xml 222 227 <span type="species:ncbi:9606">women</span>
###xml 254 262 <span type="species:ncbi:9606">patients</span>
###xml 557 565 <span type="species:ncbi:9606">patients</span>
###xml 855 863 <span type="species:ncbi:9606">patients</span>
###xml 910 918 <span type="species:ncbi:9606">patients</span>
###xml 1017 1025 <span type="species:ncbi:9606">patients</span>
###xml 1199 1207 <span type="species:ncbi:9606">patients</span>
Skeletal muscle SNARK mRNA expression is increased with obesity but not in diabetesSNARK mRNA expression was determined in vastus lateralis skeletal muscle biopsies from normal glucose tolerant and type 2 diabetic men and women (Fig. 1). Type 2 diabetic patients had fasting hyperglycaemia, and elevated HbA1c levels, compared with normal glucose tolerant individuals (p < 0.05). Individuals were stratified into two groups based on BMI. The metabolic derangements were exacerbated in the obese (BMI >31 kg/m2) vs overweight (BMI <28 kg/m2) type 2 diabetic patients, who also had increased HOMA2-IR values (p < 0.05). SNARK mRNA expression was increased 1.4-fold in obese normal glucose tolerant individuals (BMI >31 kg/m2) vs overweight normal glucose tolerant individuals (BMI <28 kg/m2). SNARK mRNA was also increased 1.4-fold in obese type 2 diabetic patients (BMI >31 kg/m2) vs overweight type 2 diabetic patients (BMI <28 kg/m2). SNARK mRNA expression was similar in normal glucose tolerant and type 2 diabetic patients, irrespectively of BMI. Fig. 1SNARK mRNA expression was determined in vastus lateralis skeletal muscle biopsies from normal glucose tolerant individuals and type 2 diabetic patients with BMI <28 kg/m2 (white bars) and BMI >31 kg/m2 (black bars). Result are reported in arbitrary units (A.U.) as means +/- SE for n = 14-18 individuals. *p < 0.05 compared with normal glucose tolerant individuals with BMI <28 kg/m2
###end p 28
###begin p 29
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 169 170 169 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 200 201 200 201 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 282 284 280 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;</italic>
###xml 306 308 304 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 382 383 380 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 143 151 <span type="species:ncbi:9606">patients</span>
SNARK mRNA expression was determined in vastus lateralis skeletal muscle biopsies from normal glucose tolerant individuals and type 2 diabetic patients with BMI <28 kg/m2 (white bars) and BMI >31 kg/m2 (black bars). Result are reported in arbitrary units (A.U.) as means +/- SE for n = 14-18 individuals. *p < 0.05 compared with normal glucose tolerant individuals with BMI <28 kg/m2
###end p 29
###begin p 30
###xml 0 54 0 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of cellular stressors on SNARK mRNA expression</bold>
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2a</xref>
###xml 232 234 232 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 265 267 261 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 319 324 315 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 401 411 397 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AMPK&#945;2</italic>
###xml 440 442 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2b</xref>
###xml 466 471 458 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 598 603 590 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 747 753 739 745 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 785 790 777 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 990 995 978 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 1013 1014 1001 1002 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1020 1030 1008 1014 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AMPK&#945;2</italic>
###xml 1048 1049 1032 1033 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1119 1121 1101 1103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;</italic>
###xml 1147 1149 1129 1131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 753 1196 745 1178 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="31">Effect of cellular stressors on <italic>SNARK</italic> mRNA expression. Cultured myoblasts were treated with palmitate (0.25&#160;mmol/l), oleate (0.25&#160;mmol/l), glucose (25&#160;mmol/l), TNF-&#945; (20&#160;ng/ml) or IL-6 (20&#160;ng/ml) for 2&#160;days followed by assessment of <italic>SNARK</italic> mRNA expression (<bold>a</bold>) and <italic>AMPK&#945;2</italic> mRNA expression (<bold>b</bold>). Results are reported in arbitrary units (A.U.) as means&#8201;&#177;&#8201;SE for <italic>n&#8201;</italic>=&#8201;5 individual cultures. *<italic>p&#8201;</italic>&lt;&#8201;0.05 compared with unstimulated control cells</p>
###xml 753 1196 745 1178 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="31">Effect of cellular stressors on <italic>SNARK</italic> mRNA expression. Cultured myoblasts were treated with palmitate (0.25&#160;mmol/l), oleate (0.25&#160;mmol/l), glucose (25&#160;mmol/l), TNF-&#945; (20&#160;ng/ml) or IL-6 (20&#160;ng/ml) for 2&#160;days followed by assessment of <italic>SNARK</italic> mRNA expression (<bold>a</bold>) and <italic>AMPK&#945;2</italic> mRNA expression (<bold>b</bold>). Results are reported in arbitrary units (A.U.) as means&#8201;&#177;&#8201;SE for <italic>n&#8201;</italic>=&#8201;5 individual cultures. *<italic>p&#8201;</italic>&lt;&#8201;0.05 compared with unstimulated control cells</p></caption>
###xml 1196 1196 1178 1178 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="125_2009_1465_Fig2_HTML" id="MO2"/>
###xml 747 1196 739 1178 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="31">Effect of cellular stressors on <italic>SNARK</italic> mRNA expression. Cultured myoblasts were treated with palmitate (0.25&#160;mmol/l), oleate (0.25&#160;mmol/l), glucose (25&#160;mmol/l), TNF-&#945; (20&#160;ng/ml) or IL-6 (20&#160;ng/ml) for 2&#160;days followed by assessment of <italic>SNARK</italic> mRNA expression (<bold>a</bold>) and <italic>AMPK&#945;2</italic> mRNA expression (<bold>b</bold>). Results are reported in arbitrary units (A.U.) as means&#8201;&#177;&#8201;SE for <italic>n&#8201;</italic>=&#8201;5 individual cultures. *<italic>p&#8201;</italic>&lt;&#8201;0.05 compared with unstimulated control cells</p></caption><graphic position="anchor" xlink:href="125_2009_1465_Fig2_HTML" id="MO2"/></fig>
Effects of cellular stressors on SNARK mRNA expressionSNARK mRNA expression was assessed in cultured myotubes treated with a variety of nutrients or cytokines for 2 days (Fig. 2a). Exposure of myotubes to either palmitate (12-fold; p < 0.01) or TNF-alpha (25-fold, p < 0.05), but not oleate, glucose or IL-6, increased SNARK mRNA expression compared with untreated myotubes, whereas expression of the AMPKalpha2 subunit was unaltered (Fig. 2b). Similar responses on SNARK mRNA expression were also observed in myotubes exposed to these metabolic stressors for 7 days (data not shown). Furthermore, SNARK mRNA expression was unaltered following exposure of myotubes to AMPK activators, including AICAR, metformin or rosiglitazone (data not shown). Fig. 2Effect of cellular stressors on SNARK mRNA expression. Cultured myoblasts were treated with palmitate (0.25 mmol/l), oleate (0.25 mmol/l), glucose (25 mmol/l), TNF-alpha (20 ng/ml) or IL-6 (20 ng/ml) for 2 days followed by assessment of SNARK mRNA expression (a) and AMPKalpha2 mRNA expression (b). Results are reported in arbitrary units (A.U.) as means +/- SE for n = 5 individual cultures. *p < 0.05 compared with unstimulated control cells
###end p 30
###begin p 31
###xml 32 37 32 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 237 242 233 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 260 261 256 257 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 267 277 263 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AMPK&#945;2</italic>
###xml 295 296 287 288 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 366 368 356 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;</italic>
###xml 394 396 384 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
Effect of cellular stressors on SNARK mRNA expression. Cultured myoblasts were treated with palmitate (0.25 mmol/l), oleate (0.25 mmol/l), glucose (25 mmol/l), TNF-alpha (20 ng/ml) or IL-6 (20 ng/ml) for 2 days followed by assessment of SNARK mRNA expression (a) and AMPKalpha2 mRNA expression (b). Results are reported in arbitrary units (A.U.) as means +/- SE for n = 5 individual cultures. *p < 0.05 compared with unstimulated control cells
###end p 31
###begin p 32
###xml 0 27 0 27 <bold xmlns:xlink="http://www.w3.org/1999/xlink">SNARK silencing in myotubes</bold>
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3a</xref>
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3b</xref>
###xml 311 317 311 317 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 317 322 317 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 379 384 379 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 426 427 426 427 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 449 450 449 450 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 520 522 518 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;</italic>
###xml 548 550 546 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 317 649 317 647 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="33"><italic>SNARK</italic> gene silencing in primary human myotubes. The effect of <italic>SNARK</italic> siRNA was determined on mRNA expression (<bold>a</bold>) and protein levels (<bold>b</bold>). Results are reported in arbitrary units (A.U.) as means&#8201;&#177;&#8201;SE for <italic>n&#8201;</italic>=&#8201;4 individual cultures. *<italic>p&#8201;</italic>&lt;&#8201;0.05 compared with myotubes treated with siRNA against a scrambled (Scr) sequence. IB, immunoblot</p>
###xml 317 649 317 647 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="33"><italic>SNARK</italic> gene silencing in primary human myotubes. The effect of <italic>SNARK</italic> siRNA was determined on mRNA expression (<bold>a</bold>) and protein levels (<bold>b</bold>). Results are reported in arbitrary units (A.U.) as means&#8201;&#177;&#8201;SE for <italic>n&#8201;</italic>=&#8201;4 individual cultures. *<italic>p&#8201;</italic>&lt;&#8201;0.05 compared with myotubes treated with siRNA against a scrambled (Scr) sequence. IB, immunoblot</p></caption>
###xml 649 649 647 647 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="125_2009_1465_Fig3_HTML" id="MO3"/>
###xml 311 649 311 647 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="33"><italic>SNARK</italic> gene silencing in primary human myotubes. The effect of <italic>SNARK</italic> siRNA was determined on mRNA expression (<bold>a</bold>) and protein levels (<bold>b</bold>). Results are reported in arbitrary units (A.U.) as means&#8201;&#177;&#8201;SE for <italic>n&#8201;</italic>=&#8201;4 individual cultures. *<italic>p&#8201;</italic>&lt;&#8201;0.05 compared with myotubes treated with siRNA against a scrambled (Scr) sequence. IB, immunoblot</p></caption><graphic position="anchor" xlink:href="125_2009_1465_Fig3_HTML" id="MO3"/></fig>
###xml 349 354 <span type="species:ncbi:9606">human</span>
SNARK silencing in myotubes The effect of SNARK gene silencing on mRNA expression (Fig. 3a) and protein level (Fig. 3b) was determined in cultured myotubes. siRNA against SNARK reduced mRNA expression by 61% and protein content by 60% compared with myotubes transfected with siRNA against a scrambled sequence. Fig. 3SNARK gene silencing in primary human myotubes. The effect of SNARK siRNA was determined on mRNA expression (a) and protein levels (b). Results are reported in arbitrary units (A.U.) as means +/- SE for n = 4 individual cultures. *p < 0.05 compared with myotubes treated with siRNA against a scrambled (Scr) sequence. IB, immunoblot
###end p 32
###begin p 33
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 62 67 62 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 109 110 109 110 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 132 133 132 133 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 203 205 201 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;</italic>
###xml 231 233 229 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 32 37 <span type="species:ncbi:9606">human</span>
SNARK gene silencing in primary human myotubes. The effect of SNARK siRNA was determined on mRNA expression (a) and protein levels (b). Results are reported in arbitrary units (A.U.) as means +/- SE for n = 4 individual cultures. *p < 0.05 compared with myotubes treated with siRNA against a scrambled (Scr) sequence. IB, immunoblot
###end p 33
###begin p 34
###xml 0 52 0 52 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Role of SNARK on glucose incorporation into glycogen</bold>
###xml 169 174 169 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 181 182 181 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 379 381 379 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 520 525 520 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 611 613 611 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 631 636 631 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 731 737 731 737 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;4</label>
###xml 745 750 745 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 920 925 920 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 1115 1117 1113 1115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;</italic>
###xml 1144 1146 1142 1144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 737 1209 737 1207 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35">Role of <italic>SNARK</italic> in glucose incorporation into glycogen. Glucose incorporation into glycogen was measured in myotubes transfected with either siRNA against a scrambled sequence (Scr) or <italic>SNARK</italic> and incubated in the absence (basal; white bars) or presence of a submaximal (6&#160;nmol/l; grey bars) or maximal (60&#160;nmol/l; black bars) concentration of insulin. Results are means&#8201;&#177;&#8201;SE for <italic>n&#8201;</italic>=&#8201;8 individuals cultures. *<italic>p&#8201;</italic>&lt;&#8201;0.05 compared with basal scrambled siRNA-transfected myotubes</p>
###xml 737 1209 737 1207 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="35">Role of <italic>SNARK</italic> in glucose incorporation into glycogen. Glucose incorporation into glycogen was measured in myotubes transfected with either siRNA against a scrambled sequence (Scr) or <italic>SNARK</italic> and incubated in the absence (basal; white bars) or presence of a submaximal (6&#160;nmol/l; grey bars) or maximal (60&#160;nmol/l; black bars) concentration of insulin. Results are means&#8201;&#177;&#8201;SE for <italic>n&#8201;</italic>=&#8201;8 individuals cultures. *<italic>p&#8201;</italic>&lt;&#8201;0.05 compared with basal scrambled siRNA-transfected myotubes</p></caption>
###xml 1209 1209 1207 1207 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="125_2009_1465_Fig4_HTML" id="MO4"/>
###xml 731 1209 731 1207 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Fig.&#160;4</label><caption><p textid="35">Role of <italic>SNARK</italic> in glucose incorporation into glycogen. Glucose incorporation into glycogen was measured in myotubes transfected with either siRNA against a scrambled sequence (Scr) or <italic>SNARK</italic> and incubated in the absence (basal; white bars) or presence of a submaximal (6&#160;nmol/l; grey bars) or maximal (60&#160;nmol/l; black bars) concentration of insulin. Results are means&#8201;&#177;&#8201;SE for <italic>n&#8201;</italic>=&#8201;8 individuals cultures. *<italic>p&#8201;</italic>&lt;&#8201;0.05 compared with basal scrambled siRNA-transfected myotubes</p></caption><graphic position="anchor" xlink:href="125_2009_1465_Fig4_HTML" id="MO4"/></fig>
Role of SNARK on glucose incorporation into glycogen Glucose incorporation into glycogen was assessed in myotubes transfected with siRNA against a scrambled sequence or SNARK (Fig. 4). Insulin increased glucose incorporation into glycogen in myotubes transfected with siRNA against a scrambled sequence (1.8- and 2.3-fold in the presence of 6 or 60 nmol/l insulin, respectively; p < 0.05 vs basal). Similar effects of insulin on glucose incorporation into glycogen were noted for myotubes transfected with siRNA against SNARK (1.8- and 2.4-fold increase in the presence of 6 or 60 nmol/l insulin, respectively; p < 0.05 vs basal). SNARK silencing did not influence basal and insulin-stimulated glucose incorporation into glycogen. Fig. 4Role of SNARK in glucose incorporation into glycogen. Glucose incorporation into glycogen was measured in myotubes transfected with either siRNA against a scrambled sequence (Scr) or SNARK and incubated in the absence (basal; white bars) or presence of a submaximal (6 nmol/l; grey bars) or maximal (60 nmol/l; black bars) concentration of insulin. Results are means +/- SE for n = 8 individuals cultures. *p < 0.05 compared with basal scrambled siRNA-transfected myotubes
###end p 34
###begin p 35
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 183 188 183 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 378 380 376 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;</italic>
###xml 407 409 405 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
Role of SNARK in glucose incorporation into glycogen. Glucose incorporation into glycogen was measured in myotubes transfected with either siRNA against a scrambled sequence (Scr) or SNARK and incubated in the absence (basal; white bars) or presence of a submaximal (6 nmol/l; grey bars) or maximal (60 nmol/l; black bars) concentration of insulin. Results are means +/- SE for n = 8 individuals cultures. *p < 0.05 compared with basal scrambled siRNA-transfected myotubes
###end p 35
###begin p 36
###xml 0 32 0 32 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Role of SNARK on lipid oxidation</bold>
###xml 131 136 131 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 143 144 143 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 252 254 252 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 295 300 295 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 426 428 426 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 439 444 439 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 456 458 456 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 496 501 496 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 585 591 585 591 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;5</label>
###xml 599 604 599 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 734 739 734 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 904 906 902 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;</italic>
###xml 933 935 931 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 591 998 591 996 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="37">Role of <italic>SNARK</italic> in lipid oxidation. Lipid oxidation was measured in myotubes transfected with siRNA against either a scrambled sequence (Scr) or <italic>SNARK</italic> and incubated in the absence (basal; white bars) or presence of either insulin (60&#160;nmol/l; grey bars) or AICAR (1&#160;mmol/l; black bars). Results are means&#8201;&#177;&#8201;SE for <italic>n&#8201;</italic>=&#8201;8 individuals cultures. *<italic>p&#8201;</italic>&lt;&#8201;0.05 compared with basal scrambled siRNA-transfected myotubes</p>
###xml 591 998 591 996 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="37">Role of <italic>SNARK</italic> in lipid oxidation. Lipid oxidation was measured in myotubes transfected with siRNA against either a scrambled sequence (Scr) or <italic>SNARK</italic> and incubated in the absence (basal; white bars) or presence of either insulin (60&#160;nmol/l; grey bars) or AICAR (1&#160;mmol/l; black bars). Results are means&#8201;&#177;&#8201;SE for <italic>n&#8201;</italic>=&#8201;8 individuals cultures. *<italic>p&#8201;</italic>&lt;&#8201;0.05 compared with basal scrambled siRNA-transfected myotubes</p></caption>
###xml 998 998 996 996 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="125_2009_1465_Fig5_HTML" id="MO5"/>
###xml 585 998 585 996 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig5"><label>Fig.&#160;5</label><caption><p textid="37">Role of <italic>SNARK</italic> in lipid oxidation. Lipid oxidation was measured in myotubes transfected with siRNA against either a scrambled sequence (Scr) or <italic>SNARK</italic> and incubated in the absence (basal; white bars) or presence of either insulin (60&#160;nmol/l; grey bars) or AICAR (1&#160;mmol/l; black bars). Results are means&#8201;&#177;&#8201;SE for <italic>n&#8201;</italic>=&#8201;8 individuals cultures. *<italic>p&#8201;</italic>&lt;&#8201;0.05 compared with basal scrambled siRNA-transfected myotubes</p></caption><graphic position="anchor" xlink:href="125_2009_1465_Fig5_HTML" id="MO5"/></fig>
Role of SNARK on lipid oxidation Lipid oxidation was determined in myotubes transfected with siRNA against a scrambled sequence or SNARK (Fig. 5). Insulin suppressed lipid oxidation in myotubes transfected with siRNA against a scrambled sequence (14%; p < 0.05) and this effect was unaltered by SNARK silencing. AICAR increased lipid oxidation in myotubes transfected with siRNA against either a scrambled sequence (3.5-fold; p < 0.01) or SNARK (3.2-fold; p < 0.01) vs the basal condition. Thus, SNARK silencing did not influence basal or insulin- or AICAR-stimulated lipid oxidation. Fig. 5Role of SNARK in lipid oxidation. Lipid oxidation was measured in myotubes transfected with siRNA against either a scrambled sequence (Scr) or SNARK and incubated in the absence (basal; white bars) or presence of either insulin (60 nmol/l; grey bars) or AICAR (1 mmol/l; black bars). Results are means +/- SE for n = 8 individuals cultures. *p < 0.05 compared with basal scrambled siRNA-transfected myotubes
###end p 36
###begin p 37
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 143 148 143 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 313 315 311 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;</italic>
###xml 342 344 340 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
Role of SNARK in lipid oxidation. Lipid oxidation was measured in myotubes transfected with siRNA against either a scrambled sequence (Scr) or SNARK and incubated in the absence (basal; white bars) or presence of either insulin (60 nmol/l; grey bars) or AICAR (1 mmol/l; black bars). Results are means +/- SE for n = 8 individuals cultures. *p < 0.05 compared with basal scrambled siRNA-transfected myotubes
###end p 37
###begin p 38
###xml 0 79 0 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of SNARK silencing on TNF-&#945;- or palmitate-induced insulin resistance</bold>
###xml 144 149 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 249 251 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6a</xref>
###xml 350 352 338 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 361 366 349 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 409 411 397 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 516 522 500 506 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;6</label>
###xml 532 537 516 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 692 697 672 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 857 862 833 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 913 914 889 890 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1009 1010 985 986 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1042 1044 1016 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;</italic>
###xml 1062 1064 1036 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 1137 1139 1106 1108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 522 1266 506 1231 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="39">Effect of <italic>SNARK</italic> silencing on TNF-&#945;- and palmitate-induced insulin resistance. Human myotubes were transfected with either siRNA against a scrambled sequence (Scr) or <italic>SNARK</italic> and incubated in the absence (basal; white bars) or presence of TNF-&#945; (20&#160;ng/ml; grey bars) or palmitate (0.25&#160;nmol/l; black bars) for 48&#160;h. The effect of <italic>SNARK</italic> siRNA silencing was determined on protein levels (<bold>a</bold>), and glucose incorporation into glycogen was measured in the absence or presence of insulin (<bold>b</bold>). Results are means&#8201;&#177;&#8201;SE for <italic>n&#8201;</italic>=&#8201;4 individuals. *<italic>p&#8201;</italic>&lt;&#8201;0.05 compared with myotubes incubated in the absence of insulin. &#8224;<italic>p&#8201;</italic>&lt;&#8201;0.05 compared with myotubes incubated in the absence of TNF-&#945; and palmitate (basal). A.U. arbitrary units; IB, immunoblot</p>
###xml 522 1266 506 1231 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="39">Effect of <italic>SNARK</italic> silencing on TNF-&#945;- and palmitate-induced insulin resistance. Human myotubes were transfected with either siRNA against a scrambled sequence (Scr) or <italic>SNARK</italic> and incubated in the absence (basal; white bars) or presence of TNF-&#945; (20&#160;ng/ml; grey bars) or palmitate (0.25&#160;nmol/l; black bars) for 48&#160;h. The effect of <italic>SNARK</italic> siRNA silencing was determined on protein levels (<bold>a</bold>), and glucose incorporation into glycogen was measured in the absence or presence of insulin (<bold>b</bold>). Results are means&#8201;&#177;&#8201;SE for <italic>n&#8201;</italic>=&#8201;4 individuals. *<italic>p&#8201;</italic>&lt;&#8201;0.05 compared with myotubes incubated in the absence of insulin. &#8224;<italic>p&#8201;</italic>&lt;&#8201;0.05 compared with myotubes incubated in the absence of TNF-&#945; and palmitate (basal). A.U. arbitrary units; IB, immunoblot</p></caption>
###xml 1266 1266 1231 1231 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="125_2009_1465_Fig6_HTML" id="MO6"/>
###xml 516 1266 500 1231 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig6"><label>Fig.&#160;6</label><caption><p textid="39">Effect of <italic>SNARK</italic> silencing on TNF-&#945;- and palmitate-induced insulin resistance. Human myotubes were transfected with either siRNA against a scrambled sequence (Scr) or <italic>SNARK</italic> and incubated in the absence (basal; white bars) or presence of TNF-&#945; (20&#160;ng/ml; grey bars) or palmitate (0.25&#160;nmol/l; black bars) for 48&#160;h. The effect of <italic>SNARK</italic> siRNA silencing was determined on protein levels (<bold>a</bold>), and glucose incorporation into glycogen was measured in the absence or presence of insulin (<bold>b</bold>). Results are means&#8201;&#177;&#8201;SE for <italic>n&#8201;</italic>=&#8201;4 individuals. *<italic>p&#8201;</italic>&lt;&#8201;0.05 compared with myotubes incubated in the absence of insulin. &#8224;<italic>p&#8201;</italic>&lt;&#8201;0.05 compared with myotubes incubated in the absence of TNF-&#945; and palmitate (basal). A.U. arbitrary units; IB, immunoblot</p></caption><graphic position="anchor" xlink:href="125_2009_1465_Fig6_HTML" id="MO6"/></fig>
###xml 1368 1370 1329 1331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 1372 1374 1333 1335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 1403 1408 1364 1369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 1426 1428 1387 1389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2a</xref>
###xml 1459 1464 1420 1425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 1536 1538 1497 1499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6b</xref>
###xml 1617 1622 1578 1583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 1845 1847 1798 1800 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 1953 1958 1906 1911 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 1980 1985 1933 1938 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 2178 2180 2127 2129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 2312 2317 2261 2266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 604 609 <span type="species:ncbi:9606">Human</span>
###xml 1352 1357 <span type="species:ncbi:9606">human</span>
Effect of SNARK silencing on TNF-alpha- or palmitate-induced insulin resistance Given that TNF-alpha and palmitate treatment markedly increased SNARK mRNA expression, we also examined whether protein levels were altered under these conditions (Fig. 6a). Exposure of myotubes to either TNF-alpha or palmitate for 48 h increased SNARK protein content (p < 0.05). SNARK silencing reduced protein content by 56% (p < 0.05), and completely prevented the effect of either TNF-alpha or palmitate to increase SNARK protein. Fig. 6Effect of SNARK silencing on TNF-alpha- and palmitate-induced insulin resistance. Human myotubes were transfected with either siRNA against a scrambled sequence (Scr) or SNARK and incubated in the absence (basal; white bars) or presence of TNF-alpha (20 ng/ml; grey bars) or palmitate (0.25 nmol/l; black bars) for 48 h. The effect of SNARK siRNA silencing was determined on protein levels (a), and glucose incorporation into glycogen was measured in the absence or presence of insulin (b). Results are means +/- SE for n = 4 individuals. *p < 0.05 compared with myotubes incubated in the absence of insulin. daggerp < 0.05 compared with myotubes incubated in the absence of TNF-alpha and palmitate (basal). A.U. arbitrary units; IB, immunoblotExposure of myotubes to TNF-alpha or palmitate induces insulin resistance in cultured human myotubes [17, 18], coincident with increased SNARK expression (Fig. 2a). Thus, we determined whether SNARK silencing prevents insulin resistance arising from these factors (Fig. 6b). Myotubes were transfected with siRNA against either a scrambled sequence or SNARK and incubated for 48 h in the absence or presence of TNF-alpha (20 ng/ml) or palmitate (0.25 mmol/l). TNF-alpha exposure decreased insulin-stimulated glucose incorporation into glycogen by 41% in the presence of 6 nmol/l (p < 0.05), but not 60 nmol/l insulin, in myotubes treated with siRNA against either a scrambled sequence or SNARK. Thus, siRNA against SNARK does not protect against TNF-alpha-induced insulin resistance. Palmitate exposure decreased insulin-stimulated glucose incorporation into glycogen by 37% in the presence of 60 nmol/l insulin (p < 0.01), but not 6 nmol/l insulin, in myotubes treated with siRNA against either a scrambled sequence or SNARK. Thus, siRNA against SNARK does not protect against palmitate-induced insulin resistance.
###end p 38
###begin p 39
###xml 10 15 10 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 170 175 166 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 335 340 327 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 391 392 383 384 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 487 488 479 480 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 520 522 510 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;</italic>
###xml 540 542 530 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 615 617 600 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 82 87 <span type="species:ncbi:9606">Human</span>
Effect of SNARK silencing on TNF-alpha- and palmitate-induced insulin resistance. Human myotubes were transfected with either siRNA against a scrambled sequence (Scr) or SNARK and incubated in the absence (basal; white bars) or presence of TNF-alpha (20 ng/ml; grey bars) or palmitate (0.25 nmol/l; black bars) for 48 h. The effect of SNARK siRNA silencing was determined on protein levels (a), and glucose incorporation into glycogen was measured in the absence or presence of insulin (b). Results are means +/- SE for n = 4 individuals. *p < 0.05 compared with myotubes incubated in the absence of insulin. daggerp < 0.05 compared with myotubes incubated in the absence of TNF-alpha and palmitate (basal). A.U. arbitrary units; IB, immunoblot
###end p 39
###begin title 40
Discussion
###end title 40
###begin p 41
###xml 89 90 89 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 104 109 104 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Snark</italic>
###xml 287 288 287 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 478 483 478 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 618 623 618 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 826 831 826 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Snark</italic>
###xml 856 857 856 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 875 880 875 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 1178 1183 1174 1179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 1272 1277 1268 1273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 1366 1371 1362 1367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Snark</italic>
###xml 1396 1397 1392 1393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 1500 1505 1496 1501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 1696 1701 1684 1689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 128 132 <span type="species:ncbi:10090">mice</span>
###xml 587 590 <span type="species:ncbi:9606">men</span>
###xml 595 600 <span type="species:ncbi:9606">women</span>
###xml 850 854 <span type="species:ncbi:10090">mice</span>
###xml 1030 1036 <span type="species:ncbi:9606">humans</span>
###xml 1207 1212 <span type="species:ncbi:9606">human</span>
###xml 1390 1394 <span type="species:ncbi:10090">mice</span>
The AMPK-related kinase SNARK plays a role in whole-body glucose and energy homeostasis [8]. Whole-body Snark-haploinsufficient mice are obese and glucose-intolerant, implicating an important role for this AMPK-related protein kinase in the regulation of energy and glucose homeostasis [8]. Here we tested the hypothesis that SNARK is involved in cellular stress responses linked to the development of insulin resistance in obesity and type 2 diabetes. We provide evidence that SNARK mRNA expression is increased in skeletal muscle from obese normal glucose tolerant and type 2 diabetic men and women. The increase in SNARK mRNA was unaltered between normal glucose tolerant and type 2 diabetic individuals irrespectively of BMI, indicating the influence of obesity, rather than diabetes per se. Based on the phenotype of the Snark-haploinsufficient mice [8], an increase in SNARK mRNA expression would be predicted to have a positive effect on energy and glucose homeostasis, but this does not appear to be the case, at least in humans. We also report that elevated levels of TNF-alpha or palmitate, systemic factors implicated in obesity-induced insulin resistance, increased SNARK expression in cultured human skeletal muscle myotubes. Nevertheless, a 60% reduction in SNARK mRNA by siRNA-mediated gene silencing (an effect similar to that achieved in whole-body Snark-haploinsufficient mice [8]), was without effect on basal or insulin-stimulated glucose uptake and lipid oxidation. Furthermore, SNARK silencing did not prevent TNF-alpha- or palmitate-induced insulin resistance in skeletal muscle. Thus, while obesity and associated systemic factors, such as TNF-alpha or palmitate increase SNARK mRNA expression, insulin resistance induced by these factors occurs via a SNARK-independent mechanism.
###end p 41
###begin p 42
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Snark</italic>
###xml 65 70 65 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Snark</italic>
###xml 270 271 270 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 322 327 322 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 491 496 487 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Snark</italic>
###xml 796 798 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 855 861 851 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Snark-</italic>
###xml 1073 1078 1069 1074 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Snark</italic>
###xml 1200 1202 1196 1198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 1256 1262 1252 1258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Snark-</italic>
###xml 1292 1297 1288 1293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Snark</italic>
###xml 1672 1677 1668 1673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Snark</italic>
###xml 24 28 <span type="species:ncbi:10090">mice</span>
###xml 353 359 <span type="species:ncbi:9606">humans</span>
###xml 515 519 <span type="species:ncbi:10090">mice</span>
###xml 874 878 <span type="species:ncbi:10090">mice</span>
###xml 1092 1096 <span type="species:ncbi:10090">mice</span>
###xml 1275 1279 <span type="species:ncbi:10090">mice</span>
###xml 1628 1632 <span type="species:ncbi:10090">mice</span>
###xml 1687 1691 <span type="species:ncbi:10090">mice</span>
Snark-haploinsufficient mice, with a 50% reduction of whole-body Snark mRNA expression, develop obesity and insulin resistance, as evidenced by increased adiposity, fatty liver, increased serum triacylglycerol, hyperinsulinaemia, hyperglycaemia and glucose intolerance [8]. Thus, our findings of increased skeletal muscle SNARK mRNA expression in obese humans and in response to elevated levels of TNF-alpha or palmitate in vitro, suggest that the metabolic phenotype observed in total-body Snark-haploinsufficient mice is unlikely to arise from a direct effect of SNARK in skeletal muscle. Rather, these results implicate a role for SNARK in other tissues, particularly since skeletal muscle expresses relatively low levels of SNARK compared with liver, kidney, intestine and testis in rodents [11]. The development of mature-onset obesity in whole-body Snark-heterozygous mice might occur from a central defect that modifies food intake and activity levels, rather than a direct effect in peripheral tissues. The absence of a basal energetic defect in skeletal muscle of Snark-heterozygous mice, as well as an unexplained increased motivation/drive for voluntary exercise supports this contention [19]. Fibre type composition and number is unaffected in Snark-heterozygous mice, indicating Snark expression and activity in tissues other than skeletal muscle may contribute to the regulation of glucose and energy homeostasis and motivation for physical activity. For example, impairments in brown adipose tissue may contribute to the obesity phenotype, since whole-body temperature and energy expenditure was reduced in these mice. Further studies using tissue-specific Snark knockout mice may resolve this paradox.
###end p 42
###begin p 43
###xml 41 42 41 42 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 314 318 314 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lkb1</italic>
###xml 334 339 334 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Stk11</italic>
###xml 534 535 534 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 624 628 624 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lkb1</italic>
###xml 644 646 644 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 664 674 664 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ampk&#945;2</italic>
###xml 692 694 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 705 715 701 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ampk&#945;1</italic>
###xml 720 730 712 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ampk&#945;2</italic>
###xml 763 765 751 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 894 898 882 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lkb1</italic>
###xml 994 995 982 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 1124 1129 1112 1117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 1274 1279 1258 1263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 1456 1461 1440 1445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 1591 1596 1575 1580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 1665 1674 1649 1654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AMPK&#945;</italic>
###xml 1769 1771 1749 1751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 1883 1888 1863 1868 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 1980 1985 1960 1965 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 350 354 <span type="species:ncbi:10090">mice</span>
###xml 638 642 <span type="species:ncbi:10090">mice</span>
###xml 675 690 <span type="species:ncbi:10090">transgenic mice</span>
###xml 757 761 <span type="species:ncbi:10090">mice</span>
###xml 1189 1195 <span type="species:ncbi:9606">humans</span>
###xml 1483 1488 <span type="species:ncbi:9606">human</span>
###xml 1753 1758 <span type="species:ncbi:9606">human</span>
The identification of an AMPK subfamily [3] raises questions about the involvement of these protein kinases in whole-body and cellular glucose and energy homeostasis, as well as the possibility that they might regulate cellular and whole-body metabolic and gene regulatory responses in a manner analogous to AMPK. Lkb1 (also known as Stk11) knockout mice have been important in the evaluation of the metabolic role of the AMPK-related kinases, since it is a master kinase that activates the majority of the members of this subfamily [3]. For example, contraction-mediated glucose uptake is inhibited in skeletal muscle from Lkb1 knockout mice [20] and kinase-dead Ampkalpha2 transgenic mice [21], but not Ampkalpha1 and Ampkalpha2 isoform-specific knockout mice [22], indicating both AMPK-dependent and AMPK-independent pathways may play a role. Moreover, skeletal muscle-selective knockout of Lkb1 increases whole-body and skeletal muscle insulin sensitivity and improves glucose homeostasis [7], implicating AMPK-related protein kinases participate in the negative regulation of insulin action. Given our observation that SNARK mRNA expression was elevated in skeletal muscle from obese humans and myotubes exposed to TNF-alpha or palmitate, we tested the hypothesis that SNARK silencing would directly alter insulin action on glucose and lipid metabolism. However, neither basal nor insulin-stimulated glucose incorporation into glycogen was altered by SNARK silencing in primary human myotubes. Furthermore, basal, as well as insulin- or AICAR-stimulated beta oxidation was unchanged by SNARK silencing. This contrasts with earlier findings which revealed that AMPKalpha subunit silencing prevents the effects of IL-6 to promote beta oxidation into human myotubes [23]. Thus, AMPK, rather than SNARK, appears to control lipid oxidation in skeletal muscle. Although siRNA against SNARK reduced mRNA expression by 60%, we cannot exclude the possibility that a total knockout of SNARK may be required to reveal effects on glucose and lipid metabolism.
###end p 43
###begin p 44
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 163 168 159 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 374 376 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 503 508 495 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 601 606 593 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 898 900 886 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 970 972 948 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 1176 1178 1139 1141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 1203 1208 1166 1171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 81 87 <span type="species:ncbi:9606">humans</span>
###xml 1023 1028 <span type="species:ncbi:9606">human</span>
Our observation of increased SNARK mRNA expression in skeletal muscle from obese humans, and in response to TNF-alpha or palmitate treatment, potentially connects SNARK to metabolic regulation in response to cellular stress signals. For example, TNF-alpha secretion from adipose tissue is increased and IL-6 serum levels are elevated in obese insulin-resistant individuals [24]. Thus, the intracellular communication between adipocytes or macrophages in obesity may provide stress signals that increase SNARK expression in skeletal muscle, which may modify insulin action. Nevertheless, siRNA against SNARK failed to prevent the development of TNF-alpha- or palmitate-induced insulin resistance on glucose incorporation into glycogen. Previous studies from our laboratory provide evidence that siRNA-mediated reduction of either the mitogen-activated protein kinase kinase kinase kinase isoform 4 [15] or the inhibitor of nuclear factor-kappabeta (NF-kappabeta) kinase [17] prevents TNF-alpha-induced insulin resistance in human skeletal muscle. Interestingly, SNARK has anti-apoptotic properties, acting through a TNF-alpha-sensitive nuclear NF-kappabeta-mediated mechanism [25]. Thus, the increase in SNARK expression may be a consequence, rather than a cause of skeletal muscle insulin resistance.
###end p 44
###begin p 45
###xml 224 229 224 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 274 279 274 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 483 488 479 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 520 525 516 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 617 622 609 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 811 817 803 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Snark-</italic>
###xml 841 842 833 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 845 850 837 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNARK</italic>
###xml 249 255 <span type="species:ncbi:9606">humans</span>
###xml 726 731 <span type="species:ncbi:9606">human</span>
###xml 835 839 <span type="species:ncbi:10090">mice</span>
In conclusion, we provide evidence against a role for SNARK in the regulation of skeletal muscle glucose or lipid metabolism. Nevertheless, obesity, but not type 2 diabetes, is associated with an increase in skeletal muscle SNARK mRNA expression in humans. This increase in SNARK mRNA expression may occur as a consequence of systemic factors associated with metabolic impairments in obesity, since exposure of myotubes to elevated levels of TNF-alpha or palmitate acutely increased SNARK mRNA expression. siRNA against SNARK failed to rescue TNF-alpha- or palmitate-induced insulin resistance, indicating changes in SNARK expression occur as a consequence, rather than a cause of insulin resistance. Based on our findings in human skeletal muscle, and the insulin-resistant and obesity phenotype in whole-body Snark-haploinsufficient mice [8], SNARK expression in metabolically active tissues beyond skeletal muscle may play a role in whole-body energy and glucose homeostasis.
###end p 45
###begin title 46
Acknowledgements
###end title 46
###begin p 47
This study was supported by grants from the European Research Council, the European Foundation for the Study of Diabetes, the Swedish Research Council, the Swedish Diabetes Association, the Strategic Research Foundation, the Knut and Alice Wallenberg Foundation, the Novo Nordisk Research Foundation and the Commission of the European Communities (Contract No LSHM-CT-2004-005272 EXGENESIS and Contract No LSHM-CT-2004-512013 EUGENE2).
###end p 47
###begin p 48
###xml 0 19 0 19 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Duality of interest</bold>
Duality of interest The authors declare that there is no duality of interest associated with this manuscript.
###end p 48
###begin p 49
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 49
###begin title 50
References
###end title 50
###begin article-title 51
Influence of AMP-activated protein kinase and calcineurin on metabolic networks in skeletal muscle
###end article-title 51
###begin article-title 52
AMPK: a key regulator of energy balance in the single cell and the whole organism
###end article-title 52
###begin article-title 53
LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1
###end article-title 53
###begin article-title 54
###xml 37 42 <span type="species:ncbi:9606">human</span>
The protein kinase complement of the human genome
###end article-title 54
###begin article-title 55
14-3-3 cooperates with LKB1 to regulate the activity and localization of QSK and SIK
###end article-title 55
###begin article-title 56
Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR
###end article-title 56
###begin article-title 57
Skeletal muscle-selective knockout of LKB1 increases insulin sensitivity, improves glucose homeostasis, and decreases TRB3
###end article-title 57
###begin article-title 58
###xml 34 38 <span type="species:ncbi:10090">mice</span>
Susceptibility of Snark-deficient mice to azoxymethane-induced colorectal tumorigenesis and the formation of aberrant crypt foci
###end article-title 58
###begin article-title 59
###xml 95 98 <span type="species:ncbi:10116">rat</span>
UVB radiation-activated genes induced by transcriptional and posttranscriptional mechanisms in rat keratinocytes
###end article-title 59
###begin article-title 60
Identification and characterization of a novel sucrose-non-fermenting protein kinase/AMP-activated protein kinase-related protein kinase, SNARK
###end article-title 60
###begin article-title 61
Regulation of SNARK activity in response to cellular stresses
###end article-title 61
###begin article-title 62
Hunting for the SNARK in metabolic disease
###end article-title 62
###begin article-title 63
Nuclear localization of SNARK; its impact on gene expression
###end article-title 63
###begin article-title 64
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human skeletal muscle cell differentiation is associated with changes in myogenic markers and enhanced insulin-mediated MAPK and PKB phosphorylation
###end article-title 64
###begin article-title 65
###xml 25 30 <span type="species:ncbi:9606">human</span>
MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-alpha-induced insulin resistance
###end article-title 65
###begin article-title 66
###xml 27 32 <span type="species:ncbi:9606">human</span>
Insulin action in cultured human skeletal muscle cells during differentiation: assessment of cell surface GLUT4 and GLUT1 content
###end article-title 66
###begin article-title 67
###xml 137 142 <span type="species:ncbi:9606">human</span>
siRNA-mediated reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle
###end article-title 67
###begin article-title 68
###xml 75 83 <span type="species:ncbi:9606">children</span>
Fatty acid-induced defects in insulin signalling, in myotubes derived from children, are related to ceramide production from palmitate rather than the accumulation of intramyocellular lipid
###end article-title 68
###begin article-title 69
###xml 112 116 <span type="species:ncbi:10090">mice</span>
Provision of a voluntary exercise environment enhances running activity and prevents obesity in Snark-deficient mice
###end article-title 69
###begin article-title 70
Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction
###end article-title 70
###begin article-title 71
A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle
###end article-title 71
###begin article-title 72
Knockout of the alpha2 but not alpha1 5'-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranosidebut not contraction-induced glucose uptake in skeletal muscle
###end article-title 72
###begin article-title 73
Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle
###end article-title 73
###begin article-title 74
###xml 69 74 <span type="species:ncbi:9606">human</span>
Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance
###end article-title 74
###begin article-title 75
Identification of SNF1/AMP kinase-related kinase as an NF-kappaB-regulated anti-apoptotic kinase involved in CD95-induced motility and invasiveness
###end article-title 75
###begin title 76
Abbreviations
###end title 76
###begin p 77
5-Aminoimidazole-4-carboxamide-1beta-4-ribofuranoside
###end p 77
###begin p 78
AMP-activated protein kinase
###end p 78
###begin p 79
Insulin resistance
###end p 79
###begin p 80
Small interfering RNA
###end p 80
###begin p 81
Sucrose, non-fermenting 1/AMP-activated protein kinase-related kinase
###end p 81

